Amended Statement of Ownership (sc 13g/a)
February 14 2019 - 4:26PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(Amendment No. 1)
Under the Securities Exchange Act of 1934
Aclaris
Therapeutics, Inc.
|
(Name of Issuer)
|
|
Common Stock, par value $0.00001
|
(Title of Class of Securities)
|
|
December 31, 2018
|
(Date of Event Which Requires Filing of this Statement)
|
Check the following box to designate the rule pursuant to which
the Schedule is filed:
|
¨
|
Rule 13d-1(b)
|
|
x
|
Rule 13d-1(c)
|
|
¨
|
Rule 13d-1(d)
|
*The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page
shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act")
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
|
1.
|
Names of Reporting Persons
I.R.S. Identification Nos. of above persons (entities only)
D. E. Shaw & Co., L.L.C.
13-3799946
|
|
|
|
|
2.
|
Check the Appropriate Box if a Member of a Group (See Instructions)
|
|
|
(a)
|
¨
|
|
|
(b)
|
¨
|
|
|
|
|
|
3.
|
SEC Use Only
|
|
|
|
|
4.
|
Citizenship or Place of Organization
Delaware
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
|
5.
|
Sole Voting Power
-0-
|
|
|
|
|
6.
|
Shared Voting Power
2,278,364
|
|
|
|
|
7.
|
Sole Dispositive Power
-0-
|
|
|
|
|
8.
|
Shared Dispositive Power
2,278,364
|
|
9.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
2,278,364
|
|
|
|
|
10.
|
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
¨
|
|
|
|
|
11.
|
Percent of Class Represented by Amount in Row (9)
5.6%
|
|
|
|
|
12.
|
Type of Reporting Person (See Instructions)
OO
|
|
1.
|
Names of Reporting Persons
I.R.S. Identification Nos. of above persons (entities only)
D. E. Shaw & Co., L.P.
13-3695715
|
|
|
|
|
2.
|
Check the Appropriate Box if a Member of a Group (See Instructions)
|
|
|
(a)
|
¨
|
|
|
(b)
|
¨
|
|
|
|
|
|
3.
|
SEC Use Only
|
|
|
|
|
4.
|
Citizenship or Place of Organization
Delaware
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
|
5.
|
Sole Voting Power
-0-
|
|
|
|
|
6.
|
Shared Voting Power
2,280,294
|
|
|
|
|
7.
|
Sole Dispositive Power
-0-
|
|
|
|
|
8.
|
Shared Dispositive Power
2,280,294
|
|
9.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
2,280,294
|
|
|
|
|
10.
|
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
¨
|
|
|
|
|
11.
|
Percent of Class Represented by Amount in Row (9)
5.6%
|
|
|
|
|
12.
|
Type of Reporting Person (See Instructions)
IA, PN
|
|
1.
|
Names of Reporting Persons
I.R.S. Identification Nos. of above persons (entities only)
David E. Shaw
|
|
|
|
|
2.
|
Check the Appropriate Box if a Member of a Group (See Instructions)
|
|
|
(a)
|
¨
|
|
|
(b)
|
¨
|
|
|
|
|
|
3.
|
SEC Use Only
|
|
|
|
|
4.
|
Citizenship or Place of Organization
United States
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
|
5.
|
Sole Voting Power
-0-
|
|
|
|
|
|
|
6.
|
Shared Voting Power
2,280,294
|
|
|
|
|
|
|
|
|
7.
|
Sole Dispositive Power
-0-
|
|
|
|
|
|
|
|
|
8.
|
Shared Dispositive Power
2,280,294
|
|
9.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
2,280,294
|
|
|
|
|
10.
|
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
¨
|
|
|
|
|
11.
|
Percent of Class Represented by Amount in Row (9)
5.6%
|
|
|
|
|
12.
|
Type of Reporting Person (See Instructions)
IN
|
Item 1.
|
|
(a)
|
Name of Issuer
|
|
Aclaris Therapeutics, Inc.
|
|
|
(b)
|
Address of Issuer's Principal Executive Offices
|
|
640 Lee Road, Suite 200
|
|
Wayne, PA 19087
|
Item 2.
|
|
(a)
|
Name of Person Filing
|
|
D. E. Shaw & Co., L.L.C.
|
|
D. E. Shaw & Co., L.P.
|
|
David E. Shaw
|
|
|
(b)
|
Address of Principal Business Office or, if none, Residence
|
|
The business address for each reporting person is:
|
|
1166 Avenue of the Americas, 9
th
Floor
|
|
New York, NY 10036
|
|
|
(c)
|
Citizenship
|
|
D. E. Shaw & Co., L.L.C. is a limited liability company organized under the laws of the state of Delaware.
|
|
D. E. Shaw & Co., L.P. is a limited partnership organized under the laws of the state of Delaware.
|
|
David E. Shaw is a citizen of the United States of America.
|
|
|
(d)
|
Title of Class of Securities
|
|
Common Stock, par value $0.00001
|
|
|
(e)
|
CUSIP Number
|
|
00461U105
|
Item 3.
|
If this statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:
|
Not Applicable
As of December 31, 2018:
(a)
|
Amount beneficially owned:
|
|
D. E. Shaw & Co., L.L.C.:
|
2,278,364 shares
|
|
|
This is composed of (i) 1,530,295 shares in the name of D. E. Shaw Valence Portfolios, L.L.C., (ii) 745,544 shares in the name of D. E. Shaw Oculus Portfolios, L.L.C., and (iii) 2,525 shares in the name of D. E. Shaw Asymptote Portfolios, L.L.C.
|
|
|
|
|
D. E. Shaw & Co., L.P.:
|
2,280,294 shares
|
|
|
This is composed of (i) 1,530,295 shares in the name of D. E. Shaw Valence Portfolios, L.L.C., (ii) 745,544 shares in the name of D. E. Shaw Oculus Portfolios, L.L.C., (iii) 2,525 shares in the name of D. E. Shaw Asymptote Portfolios, L.L.C., and (iv) 1,930 shares under the management of D. E. Shaw Investment Management, L.L.C.
|
|
|
|
|
David E. Shaw:
|
2,280,294 shares
|
|
|
This is composed of (i) 1,530,295 shares in the name of D. E. Shaw Valence Portfolios, L.L.C., (ii) 745,544 shares in the name of D. E. Shaw Oculus Portfolios, L.L.C., (iii) 2,525 shares in the name of D. E. Shaw Asymptote Portfolios, L.L.C., and (iv) 1,930 shares under the management of D. E. Shaw Investment Management, L.L.C.
|
(b)
|
Percent of class:
|
|
|
D. E. Shaw & Co., L.L.C.:
|
5.6%
|
|
D. E. Shaw & Co., L.P.:
|
5.6%
|
|
David E. Shaw:
|
5.6%
|
(c)
|
Number of shares to which the person has:
|
|
(i)
|
Sole power to vote or to direct the vote:
|
|
|
|
D. E. Shaw & Co., L.L.C.:
|
-0- shares
|
|
|
D. E. Shaw & Co., L.P.:
|
-0- shares
|
|
|
David E. Shaw:
|
-0- shares
|
|
(ii)
|
Shared power to vote or to direct the vote:
|
|
|
|
D. E. Shaw & Co., L.L.C.:
|
2,278,364 shares
|
|
|
D. E. Shaw & Co., L.P.:
|
2,280,294 shares
|
|
|
David E. Shaw:
|
2,280,294 shares
|
|
(iii)
|
Sole power to dispose or to direct the disposition of:
|
|
|
|
D. E. Shaw & Co., L.L.C.:
|
-0- shares
|
|
|
D. E. Shaw & Co., L.P.:
|
-0- shares
|
|
|
David E. Shaw:
|
-0- shares
|
|
(iv)
|
Shared power to dispose or to direct the disposition of:
|
|
|
|
D. E. Shaw & Co., L.L.C.:
|
2,278,364 shares
|
|
|
D. E. Shaw & Co., L.P.:
|
2,280,294 shares
|
|
|
David E. Shaw:
|
2,280,294 shares
|
David E. Shaw does not own any shares directly. By virtue of
David E. Shaw’s position as President and sole shareholder of D. E. Shaw & Co., Inc., which is the general partner of
D. E. Shaw & Co., L.P., which in turn is the investment adviser of D. E. Shaw Valence Portfolios, L.L.C. and D. E. Shaw Oculus
Portfolios, L.L.C. and the managing member of D. E. Shaw Investment Management, L.L.C. and D. E. Shaw Adviser, L.L.C., which in
turn is the investment adviser of D. E. Shaw Asymptote Portfolios, L.L.C., and by virtue of David E. Shaw’s position as President
and sole shareholder of D. E. Shaw & Co. II, Inc., which is the managing member of D. E. Shaw & Co., L.L.C.,
which in turn is the manager of D. E. Shaw Valence Portfolios, L.L.C. and D. E. Shaw Oculus Portfolios, L.L.C. and the managing
member of D. E. Shaw Manager, L.L.C., which in turn is the manager of D. E. Shaw Asymptote Portfolios, L.L.C., David E. Shaw
may be deemed to have the shared power to vote or direct the vote of, and the shared power to dispose or direct the disposition
of, the 2,280,294 shares as described above constituting 5.6% of the outstanding shares and, therefore, David E. Shaw may be deemed
to be the beneficial owner of such shares. David E. Shaw disclaims beneficial ownership of such 2,280,294 shares.
Item 5.
|
Ownership of Five Percent or Less of a Class
|
Not Applicable
Item 6.
|
Ownership of More than Five Percent on Behalf of Another Person.
|
Not Applicable
Item 7.
|
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
|
Not Applicable
Item 8.
|
Identification and Classification of Members of the Group
|
Not Applicable
Item 9.
|
Notice of Dissolution of Group
|
Not Applicable
By signing below, each of D. E. Shaw & Co., L.L.C., D. E. Shaw & Co., L.P., and David E. Shaw certify that, to the best of such reporting person’s knowledge and belief, the securities
referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control
of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction
having such purposes or effect.
SIGNATURE
After reasonable inquiry and to the best of their knowledge
and belief, the undersigned certify that the information set forth in this statement is true, complete and correct. Powers of Attorney,
dated March 1, 2017, granted by David E. Shaw in favor of Nathan Thomas, are attached hereto.
Dated: February 14, 2019
|
D. E. Shaw & Co., L.L.C.
|
|
|
|
|
By:
|
/s/ Nathan Thomas
|
|
|
Nathan Thomas
|
|
|
Authorized Signatory
|
|
|
|
|
D. E. Shaw & Co., L.P.
|
|
|
|
|
By:
|
/s/ Nathan Thomas
|
|
|
Nathan Thomas
|
|
|
Chief Compliance Officer
|
|
|
|
|
David E. Shaw
|
|
|
|
|
By:
|
/s/ Nathan Thomas
|
|
|
Nathan Thomas
|
|
|
Attorney-in-Fact for David E. Shaw
|
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jul 2023 to Jul 2024